Expertise in
4
conditions

Dr. Antonio Giordano

Oncology
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 
Offers Telehealth
Expertise in
4
conditions
Dana-Farber Cancer Institute
450 Brookline Ave, 
Boston, MA 

Overview

Antonio Giordano is an Oncologist in Boston, Massachusetts. Dr. Giordano is highly rated in 4 conditions, according to our data. His top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in SC

Hospital Affiliations

Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215
Other Locations
Dana-Farber Cancer Institute-Chestnut Hill
300 Boylston St, Chestnut Hill, MA 02467

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients
A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy
Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy
Enrollment Status: Terminated
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: OPC
Study Phase: Phase 1
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Procedure
View 6 Less Clinical Trials
Similar Doctors
Expertise in
21
conditions
Dr. Matthew Davids
Oncology
Expertise in
21
conditions
Dr. Matthew Davids
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Davids is an Oncologist in Boston, Massachusetts. Dr. Davids is highly rated in 21 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Tissue Biopsy, and Bone Marrow Transplant.

Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology
Expertise in
44
conditions
Dr. Eric Jacobsen
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Jacobsen is an Oncologist in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Daniel Deangelo
Expertise in
36
conditions
Dr. Daniel Deangelo
Oncology
Expertise in
36
conditions
Dr. Daniel Deangelo
Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Deangelo is an Oncologist in Boston, Massachusetts. Dr. Deangelo is highly rated in 36 conditions, according to our data. His top areas of expertise are Systemic Mastocytosis, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Antonio Giordano

How do I make an appointment with Dr. Antonio Giordano?

You can book an appointment with Dr. Antonio Giordano by calling their office at 877-442-3324. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Antonio Giordano a top-rated expert for Inflammatory Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Antonio Giordano is classified as an Advanced expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Antonio Giordano specialize in?

While Dr. Antonio Giordano is a Oncology, they have specific expertise in Inflammatory Breast Cancer, Breast Cancer, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Antonio Giordano accept my insurance?

Dr. Antonio Giordano accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 877-442-3324 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Giordano's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile